search
Back to results

Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer (SLOT)

Primary Purpose

Microsatellite Stable Metastatic Colorectal Cancer

Status
Recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Regorafenib
Toripalimab
High/low-dose radiotherapy
Regorafenib
Sponsored by
Fudan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Microsatellite Stable Metastatic Colorectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥18 years old An Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Life expectancy of at least 3 months Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum At least two evaluable metastatic lesions for SABR and LDRT according to RECIST 1.1 Progressed on or after the standard first-and second-line therapies or stopped standard therapy because of unacceptable toxic effects Previous radiotherapy completed at least 4 weeks before randomization Adequate bone-marrow, hepatic, and renal function: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST≤2.5 ULN, Cr≤1 ULN Sign the informed consent and have good compliance Exclusion Criteria: History of previous treatment with regorafenib and ICIs such as anti-PD-1 or anti-PD-L1 mAbs Current severe cardiovascular diseases such as unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment Active autoimmune diseases and immunodeficiencies, known history of organ transplantation, or systematic use of immunosuppressive agents Active Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection: HBsAg positive or HBV DNA positive, anti-HCV antibody testing positive and confirmatory HCV RNA positive Positive human immunodeficiency virus (HIV) infection, active syphilis infection, or active pulmonary tuberculosis infection Severe infections requiring systemic antibiotics, antifungal or antiviral therapy Uncontrollable pleural effusion, pericardial effusion, or ascites Other malignancies within 5 years before recruitment, except for non-melanoma skin cancer, superficial bladder cancer, cervical carcinoma in situ, or breast cancer in situ that had been effectively treated. Known history of severe neurological or mental illness such as schizophrenia, dementia, or epilepsy Known history of allergy to any component involved in this study. Pregnancy or breast-feeding women

Sites / Locations

  • Fudan University Shanghai Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

monotherapy

combination therapies

Arm Description

a total of 45 patients will receive regorafenib monotherapy.

a total of 45 patients will first receive 1 cycle of regorafenib and toripalimab followed by SABR/LDRT radiotherapy. Regorafenib and toripalimab will be continued after the completion of radiotherapy.

Outcomes

Primary Outcome Measures

ORR
The percentage of patients with objective response in all metastatic lesions. Objective response is defined as complete response (CR) or partial response (PR) per response evaluation criteria (RECIST v1.1) and the immune-related response criteria (iRECIST) after treatment.

Secondary Outcome Measures

DCR
The percentage of patients with disease control in all metastatic lesions. Disease control is defined as CR, PR, or stable disease (SD) per RECIST v1.1 and iRECIST after treatment.
DoR
Defined as the time between PR/CR and subsequent progression disease (PD) per RECIST v1.1 and iRECIST or death from any cause.
PFS
Defined as the time from initiation of treatment to PD or death from any cause.
OS
Defined as the time from initiation of treatment to death from any cause.
Adverse events
The percentage of patients with treatment-related acute toxicities as assessed by NCI CTCAE v5.0, from treatment initiation until 90 days upon completion of immunotherapy.

Full Information

First Posted
July 19, 2023
Last Updated
July 19, 2023
Sponsor
Fudan University
search

1. Study Identification

Unique Protocol Identification Number
NCT05963490
Brief Title
Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Acronym
SLOT
Official Title
A Prospective, Randomized, Controlled Phase II Trial of Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab as Third-line Treatment in Patients With Metastatic Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 25, 2023 (Actual)
Primary Completion Date
April 25, 2024 (Anticipated)
Study Completion Date
April 25, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fudan University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study compares the efficacy and safety of regorafenib alone or in combination with stereotactic ablative radiotherapy (SABR) and low-dose radiotherapy (LDRT) plus toripalimab in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC). Patients are randomly assigned (1:1) into the control arm and the experimental arm. Control arm: a total of 45 patients will receive regorafenib monotherapy. Experimental arm: a total of 45 patients will first receive 1 cycle of regorafenib and toripalimab followed by SABR/LDRT radiotherapy. Regorafenib and toripalimab will be continued after the completion of radiotherapy. The objective response rate (ORR), survival benefits, and adverse effects will be analyzed.
Detailed Description
Control arm: regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle. Experimental arm: regorafenib is administered 80 mg once daily on days 1-21 of each 28 days cycle with intravenous toripalimab 240 mg every 3 weeks. Radiotherapy regimes include 4-8 fractions of 8-12Gy via SABR and up to 1-10Gy at 0.5-2Gy/fraction via LDRT.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Microsatellite Stable Metastatic Colorectal Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
monotherapy
Arm Type
Active Comparator
Arm Description
a total of 45 patients will receive regorafenib monotherapy.
Arm Title
combination therapies
Arm Type
Experimental
Arm Description
a total of 45 patients will first receive 1 cycle of regorafenib and toripalimab followed by SABR/LDRT radiotherapy. Regorafenib and toripalimab will be continued after the completion of radiotherapy.
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Other Intervention Name(s)
Stivarga
Intervention Description
Regorafenib 120 mg orally once daily on days 1-21 of each 28 days cycle.
Intervention Type
Drug
Intervention Name(s)
Toripalimab
Intervention Description
240 mg intravenously every 3 weeks
Intervention Type
Radiation
Intervention Name(s)
High/low-dose radiotherapy
Intervention Description
4-8 fractions of 8-12Gy via SABR and up to 1-10Gy at 0.5-2Gy/fraction via LDRT.
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Intervention Description
Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
Primary Outcome Measure Information:
Title
ORR
Description
The percentage of patients with objective response in all metastatic lesions. Objective response is defined as complete response (CR) or partial response (PR) per response evaluation criteria (RECIST v1.1) and the immune-related response criteria (iRECIST) after treatment.
Time Frame
Up to 1 year
Secondary Outcome Measure Information:
Title
DCR
Description
The percentage of patients with disease control in all metastatic lesions. Disease control is defined as CR, PR, or stable disease (SD) per RECIST v1.1 and iRECIST after treatment.
Time Frame
Up to 1 year
Title
DoR
Description
Defined as the time between PR/CR and subsequent progression disease (PD) per RECIST v1.1 and iRECIST or death from any cause.
Time Frame
Up to 1 year
Title
PFS
Description
Defined as the time from initiation of treatment to PD or death from any cause.
Time Frame
Up to 3 years
Title
OS
Description
Defined as the time from initiation of treatment to death from any cause.
Time Frame
Up to 3 years
Title
Adverse events
Description
The percentage of patients with treatment-related acute toxicities as assessed by NCI CTCAE v5.0, from treatment initiation until 90 days upon completion of immunotherapy.
Time Frame
Up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥18 years old An Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Life expectancy of at least 3 months Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum At least two evaluable metastatic lesions for SABR and LDRT according to RECIST 1.1 Progressed on or after the standard first-and second-line therapies or stopped standard therapy because of unacceptable toxic effects Previous radiotherapy completed at least 4 weeks before randomization Adequate bone-marrow, hepatic, and renal function: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST≤2.5 ULN, Cr≤1 ULN Sign the informed consent and have good compliance Exclusion Criteria: History of previous treatment with regorafenib and ICIs such as anti-PD-1 or anti-PD-L1 mAbs Current severe cardiovascular diseases such as unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment Active autoimmune diseases and immunodeficiencies, known history of organ transplantation, or systematic use of immunosuppressive agents Active Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection: HBsAg positive or HBV DNA positive, anti-HCV antibody testing positive and confirmatory HCV RNA positive Positive human immunodeficiency virus (HIV) infection, active syphilis infection, or active pulmonary tuberculosis infection Severe infections requiring systemic antibiotics, antifungal or antiviral therapy Uncontrollable pleural effusion, pericardial effusion, or ascites Other malignancies within 5 years before recruitment, except for non-melanoma skin cancer, superficial bladder cancer, cervical carcinoma in situ, or breast cancer in situ that had been effectively treated. Known history of severe neurological or mental illness such as schizophrenia, dementia, or epilepsy Known history of allergy to any component involved in this study. Pregnancy or breast-feeding women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhen Zhang, MD, PHD
Phone
18801735029
Email
zhen_zhang@fudan.edu.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhen Zhang, MD, PHD
Organizational Affiliation
Fudan University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhen Zhang, MD, PHD
Phone
18801735029
Email
zhen_zhang@fudan.edu.cn

12. IPD Sharing Statement

Learn more about this trial

Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

We'll reach out to this number within 24 hrs